fascaplysine has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, S; Kim, J; Kim, Y; Kim, YJ; Ko, YS; Lee, YM; Lim, JH; Mah, S; Nam, TJ; Oh, TI; Reddy, RH | 1 |
| Fang, H; Li, Y; Liu, N; Xu, W | 1 |
1 review(s) available for fascaplysine and Neoplasms
| Article | Year |
|---|---|
Recent research in selective cyclin-dependent kinase 4 inhibitors for anti-cancer treatment.
Topics: Antineoplastic Agents; Carbazoles; Cyclin-Dependent Kinase 4; G1 Phase; Humans; Indoles; Neoplasms; Pyrimidines; Quinones | 2009 |
1 other study(ies) available for fascaplysine and Neoplasms
| Article | Year |
|---|---|
Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Inhibitor of Apoptosis Proteins; Mice, Inbred BALB C; Molecular Docking Simulation; Neoplasms; Neovascularization, Pathologic; Receptor, trkA; Survivin; Vascular Endothelial Growth Factor Receptor-2 | 2017 |